What is Zacks Research’s Estimate for BAX Q1 Earnings?

Baxter International Inc. (NYSE:BAXFree Report) – Equities researchers at Zacks Research reduced their Q1 2025 EPS estimates for shares of Baxter International in a research report issued on Thursday, March 13th. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical instruments supplier will earn $0.49 per share for the quarter, down from their prior forecast of $0.50. The consensus estimate for Baxter International’s current full-year earnings is $2.48 per share. Zacks Research also issued estimates for Baxter International’s Q2 2025 earnings at $0.60 EPS, Q3 2025 earnings at $0.66 EPS, Q1 2026 earnings at $0.52 EPS, Q2 2026 earnings at $0.65 EPS, Q3 2026 earnings at $0.73 EPS, FY2026 earnings at $2.63 EPS and FY2027 earnings at $2.82 EPS.

BAX has been the subject of a number of other reports. Barclays increased their target price on shares of Baxter International from $39.00 to $41.00 and gave the company an “overweight” rating in a research report on Monday, March 10th. JPMorgan Chase & Co. reduced their target price on shares of Baxter International from $38.00 to $36.00 and set a “neutral” rating for the company in a research report on Friday, February 21st. Argus upgraded shares of Baxter International from a “hold” rating to a “buy” rating in a research note on Monday, February 24th. The Goldman Sachs Group assumed coverage on shares of Baxter International in a research note on Wednesday, February 26th. They set a “buy” rating and a $42.00 price target on the stock. Finally, Citigroup dropped their price target on shares of Baxter International from $37.00 to $35.00 and set a “neutral” rating on the stock in a research note on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $38.56.

Read Our Latest Report on Baxter International

Baxter International Stock Up 0.3 %

Baxter International stock opened at $34.64 on Monday. Baxter International has a twelve month low of $28.34 and a twelve month high of $43.99. The firm has a 50 day moving average price of $32.46 and a 200-day moving average price of $33.95. The company has a market capitalization of $17.72 billion, a P/E ratio of -27.06, a P/E/G ratio of 0.93 and a beta of 0.60. The company has a quick ratio of 1.09, a current ratio of 1.43 and a debt-to-equity ratio of 1.31.

Baxter International (NYSE:BAXGet Free Report) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported $0.58 earnings per share for the quarter, beating analysts’ consensus estimates of $0.52 by $0.06. Baxter International had a negative net margin of 5.05% and a positive return on equity of 16.67%. The firm had revenue of $2.75 billion during the quarter, compared to the consensus estimate of $2.67 billion.

Baxter International Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 1st. Shareholders of record on Friday, February 28th will be paid a $0.17 dividend. This represents a $0.68 annualized dividend and a yield of 1.96%. The ex-dividend date of this dividend is Friday, February 28th. Baxter International’s dividend payout ratio is presently -53.13%.

Institutional Trading of Baxter International

Institutional investors and hedge funds have recently bought and sold shares of the company. CoreFirst Bank & Trust purchased a new stake in Baxter International in the 4th quarter worth approximately $26,000. Riverview Trust Co raised its position in shares of Baxter International by 5,488.2% during the 4th quarter. Riverview Trust Co now owns 950 shares of the medical instruments supplier’s stock valued at $28,000 after buying an additional 933 shares in the last quarter. LRI Investments LLC raised its position in shares of Baxter International by 60.8% during the 3rd quarter. LRI Investments LLC now owns 1,560 shares of the medical instruments supplier’s stock valued at $59,000 after buying an additional 590 shares in the last quarter. CKW Financial Group raised its position in shares of Baxter International by 100.0% during the 3rd quarter. CKW Financial Group now owns 2,200 shares of the medical instruments supplier’s stock valued at $81,000 after buying an additional 1,100 shares in the last quarter. Finally, Bruce G. Allen Investments LLC raised its position in shares of Baxter International by 247.3% during the 4th quarter. Bruce G. Allen Investments LLC now owns 2,622 shares of the medical instruments supplier’s stock valued at $76,000 after buying an additional 1,867 shares in the last quarter. 90.19% of the stock is currently owned by hedge funds and other institutional investors.

Baxter International Company Profile

(Get Free Report)

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.

Further Reading

Earnings History and Estimates for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.